Jacobs Solutions Inc. (NYSE:J) reported better-than-expected fourth-quarter earnings on Thursday.The company reported fourth-quarter gross revenue of $3.2 billion, a 6.6% increase from the same period a year earlier, and adjusted net revenue of $2.2 billion, up 5.8%.Adjusted EPS for the quarter was $1.75, compared with an estimate of $1.68, and revenue of $3.155 billion exceeded the $2.261 billion estimate.Chair and CEO Bob Pragada said, “We are pleased to have met or exceeded all our key metrics for FY25. ...

Core Insights - Dole plc reported third-quarter adjusted earnings below expectations, with adjusted earnings per share at $0.16 compared to the analyst consensus of $0.18, while revenue was $2.28 billion, exceeding estimates of $2.19 billion and reflecting a 10.5% year-over-year increase [1][2] Financial Performance - Net income declined by 35.7% to $13.8 million, primarily due to a $10.2 million loss from discontinued operations related to the sale of its Fresh Vegetables division [2] - Adjusted EBITDA for the Fresh Fruit segment fell by 36.7% to $27.2 million, impacted by higher banana costs due to Tropical Storm Sara in Honduras and rising sourcing costs for pineapples and plantains [3] Business Outlook - Despite the earnings shortfall, Dole reaffirmed its confidence in the outlook, expecting full-year adjusted EBITDA to reach the upper end of its target range of $380 million to $390 million [4]

Hey, John. So, it's a miss on the top and bottom line for Block. Those shares down more than 8% right now.Adjusted EPS coming in at 54 cents versus the 67 cent estimate. That is on revenue of 6.11% billion for the quarter versus 6.31% billion expected. This is the fourth straight quarter the company has reported a double miss and its sixth straight quarter that it's missed on revenue.Adjusted Ibida also coming in light at 833 million versus a street estimate of 840 million. I did just talk catch up with CFO ...

Market Overview - U.S. stocks showed mixed performance with the Nasdaq Composite falling over 50 points, while the Dow increased by 0.03% to 47,327.39 and the S&P 500 decreased by 0.09% to 6,790.33 [1] - Energy shares rose by 1.1%, while consumer staples stocks fell by 0.7% [1] Company Earnings - Cummins Inc (NYSE:CMI) reported adjusted earnings of $5.59 per share, surpassing market expectations of $4.81 per share, with quarterly sales of $8.317 billion compared to anticipated sales of $7.971 billion [2] Commodity Prices - Oil prices increased by 0.1% to $59.63, gold rose by 0.6% to $4,016.60, silver gained 0.6% to $48.300, and copper saw a slight increase of 0.1% to $4.9905 [5] European Market Performance - European shares mostly declined, with the eurozone's STOXX 600 falling by 0.3%, while Spain's IBEX 35 Index rose by 0.2% [6] Asian Market Performance - Asian markets closed predominantly higher, with Japan's Nikkei 225 surging 1.34% and Hong Kong's Hang Seng gaining 2.12% [7] Job Cuts Announcement - U.S.-based employers announced 153,074 job cuts in October, a significant increase from 54,064 in the previous month [8] Stock Movements - Baiya International Group Inc. (NASDAQ:BIYA) shares surged by 121% to $0.6032, while Forge Global Holdings, Inc. (NYSE:FRGE) rose by 68% to $43.83 following an acquisition agreement with Charles Schwab [9] - MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares increased by 43% to $0.1801, whereas DIH Holding US, Inc. (NASDAQ:DHAI) shares dropped by 64% to $0.6608 [9] - ACV Auctions Inc. (NYSE:ACVA) fell by 37% to $5.13 after cutting its full-year sales guidance, and B of A Securities downgraded the stock from Buy to Underperform [9] - Aspen Aerogels, Inc. (NYSE:ASPN) shares decreased by 36% to $4.74 after lowering its full-year earnings and sales guidance [9]

Core Insights - Evercore Inc. (EVR) reported third-quarter 2025 adjusted earnings per share (EPS) of $3.48, exceeding the Zacks Consensus Estimate of $3.01 and up from $2.04 in the prior-year quarter [1][9] - The company achieved record adjusted net revenues of $1.05 billion, a 41.6% increase year over year, driven by strong performance in Investment Banking and Equities [3][9] - Total expenses rose by 34.4% year over year to $822.7 million, impacting operating margins [3][9] Revenue and Expenses - Investment Banking & Equities segment net revenues increased by 41% year over year to $1.04 billion, primarily due to higher advisory fees and growth in commissions [4] - Investment Management segment net revenues were $22.7 million, up 5.8% from the prior-year quarter, but operating income decreased by 56.2% year over year [5] - The adjusted compensation ratio improved to 65% from 66% in the prior-year quarter, while the adjusted operating margin decreased to 21.8% from 28.9% [3] Balance Sheet and Liquidity - As of September 30, 2025, cash and cash equivalents stood at $851.9 million, with investment securities and certificates of deposit totaling $1.6 billion [6] - Current assets exceeded current liabilities by $2 billion, indicating a strong liquidity position [6] Capital Distribution - On October 28, 2025, the company declared a quarterly dividend of 84 cents per share, payable on December 12 to common stockholders of record as of November 28 [7] - In the reported quarter, Evercore repurchased 0.2 million shares at an average price of $329.8 [7] Market Reaction - Despite solid quarterly results, EVR shares fell by 9.1% in the trading session following the earnings report, likely due to broader market trends [2]

Core Insights - Bio-Rad Laboratories, Inc. reported Q3 2025 adjusted EPS of $2.26, missing estimates by 1.74% but showing an 11.9% increase year over year [1][8] - The company's revenues reached $653 million, exceeding expectations by 0.24% and reflecting a 0.5% year-over-year growth [3][8] - Bio-Rad's gross margin contracted by 219 basis points to 52.6%, while operating profit increased by 1.2% [5][8] Financial Performance - The GAAP loss was reported at $12.70 per share, a significant decline from EPS of $23.34 a year ago [2] - Gross profit decreased by 3.5% to $343.4 million, with operating expenses down 4.6% year over year [5] - Cash and cash equivalents at the end of Q3 were $1.42 billion, up from $1.37 billion at the end of Q2 [6] Segment Analysis - Life Science segment sales totaled $261.8 million, a 0.3% increase year over year, but down 1.5% at constant exchange rates [4] - Clinical Diagnostics segment net sales were $391.2 million, up 0.6% year over year, with a decline of 1.8% at constant exchange rates due to lower reimbursement rates in China [4] Guidance and Outlook - Bio-Rad reiterated its full-year 2025 guidance, projecting adjusted, currency-neutral revenue growth of approximately 0-1% [9] - The adjusted operating margin for the full year is expected to be between 12% and 13% [9] - The company anticipates a return to growth in the Diagnostics segment in Q4, with improvements expected from the quality controls portfolio [11]

Core Insights - Booz Allen Hamilton Holding Corp. (BAH) reported second-quarter fiscal 2026 earnings that met the Zacks Consensus Estimate, but revenues fell short, leading to a 6.4% decline in stock price since the results were released on October 24, 2025 [1] Financial Performance - Quarterly adjusted EPS was $1.49, aligning with estimates but down 17.7% year-over-year [4][9] - Revenues totaled $2.89 billion, missing consensus estimates by 3.1% and decreasing 8.15% year-over-year [4][9] - Adjusted EBITDA was $324 million, a decrease of 11% from the previous year, but exceeded estimates [7] Fiscal 2026 Outlook - BAH expects fiscal 2026 revenues to be between $11.3 billion and $11.5 billion, lower than the previous guidance of $12 billion to $12.5 billion [2] - The midpoint of the revenue guidance ($11.40 billion) is slightly below the Zacks Consensus Estimate of $11.42 billion [2] - Adjusted diluted EPS is projected to be in the range of $5.45 to $5.65, down from prior guidance of $6.20 to $6.55 [3] Backlog and Book-to-Bill Ratio - Total backlog increased by 2.9% year-over-year to $40 billion, but fell short of expectations [5] - Funded backlog decreased by 6.1% to $5.4 billion, while unfunded backlog rose by 19.3% to $10.67 billion [5] - The book-to-bill ratio was 1.7, down from 2.4 in the previous year [6] Balance Sheet and Cash Flow - Cash and cash equivalents at the end of the quarter were $816 million, down from $885 million [8] - Long-term debt decreased to $3.88 billion from $3.92 billion [8] - Free cash flow was reported at $395 million, with net cash from operating activities at $421 million [8]

Core Insights - Wayfair shares increased by over 21% following the release of quarterly results that exceeded Wall Street expectations, driven by higher sales and improved cost discipline [1] Financial Performance - The quarterly results showcased a significant rise in sales, contributing to the positive market reaction [1] - The company demonstrated enhanced cost management, which played a crucial role in surpassing analyst forecasts [1]

Core Insights - Quest Diagnostics Inc. reported third-quarter 2025 adjusted earnings per share (EPS) of $2.60, exceeding the Zacks Consensus Estimate by 3.59% and up 13% year-over-year [1][8] - The company's revenues for the quarter rose 15.2% year-over-year to $2.82 billion, surpassing the Zacks Consensus Estimate by 3.45% [3][8] - The gross margin expanded by 110 basis points to 33.7%, indicating improved profitability [5][8] Revenue Performance - Diagnostic Information Services revenues increased by 13.5% year-over-year to $2.76 billion, exceeding projections [3] - Test volumes rose by 12.5% year-over-year, contributing to revenue growth [4][8] - Revenue per requisition saw a slight increase of 0.8% year-over-year [4] Margin and Cost Analysis - The cost of services for the quarter was $1.87 billion, up 11.3% year-over-year, while gross profit rose 17% to $949 million [5] - Selling, General and Administrative (SG&A) expenses were $501 million, an increase of 11.8% from the previous year [5] - The adjusted operating margin improved to 15.9%, reflecting a 132-basis point expansion year-over-year [5] Financial Position - At the end of Q3 2025, the company had cash and cash equivalents of $432 million, up from $319 million at the end of Q2 [6] - Cumulative net cash provided by operating activities reached $1.42 billion, compared to $858 million in the same period last year [6] - The company has a five-year annualized dividend growth rate of 7.21% [6] Guidance and Outlook - Quest Diagnostics updated its full-year 2025 revenue guidance to a range of $10.96 billion to $11.00 billion, indicating a year-over-year increase of 11% to 11.4% [7] - Adjusted EPS guidance was raised to a range of $9.76 to $9.84, up from the previous range of $9.63 to $9.83 [7] Strategic Developments - The quarter included a joint venture agreement with Corewell Health for lab services in Michigan and the acquisition of dialysis testing assets from Fresenius Medical Care [10] - The company received FDA breakthrough device designation for the Haystack MRD test and formed collaborations with Mass General Brigham and Rutgers Cancer Institute [10]

Core Insights - Domino's Pizza, Inc. (DPZ) reported third-quarter fiscal 2025 results with earnings and revenues exceeding the Zacks Consensus Estimate, leading to a 4% increase in shares during pre-market trading [1] Financial Performance - Adjusted earnings per share (EPS) for the quarter were $4.08, surpassing the Zacks Consensus Estimate of $3.99, although this represents a 2.6% decline from $4.19 in the same quarter last year [3][10] - Revenues reached $1,147.1 million, beating the consensus mark of $1,139 million, and reflecting a year-over-year increase of 6.2% driven by U.S. franchise royalties and higher supply-chain revenues [3][10] Operational Highlights - The company achieved positive order growth in the U.S., supported by the "Best Deal Ever" promotion and innovations in stuffed-crust pizza, enhancing momentum in both delivery and carryout channels [2] - Domino's opened 214 net new stores during the quarter, contributing to a 6.3% rise in global retail sales year-over-year [4][10] Sales Metrics - Global retail sales (excluding foreign currency impact) increased by 6.3% year-over-year, with U.S. store sales rising by 7% and international sales by 5.7% [5] - Comparable store sales (comps) in the U.S. rose by 5.2%, with domestic company-owned stores seeing a 3.4% increase and franchise stores rising by 5.3% [5][6] Margin Analysis - Gross margin expanded by 90 basis points year-over-year to 40.1%, although the gross margin for U.S. company-owned stores contracted by 50 basis points to 16.3% due to increased food costs and wage expenses [8] Balance Sheet Overview - As of September 7, 2025, cash and cash equivalents totaled $139.7 million, down from $186.1 million at the end of the previous year [11] - Long-term debt increased to $4.81 billion from $3.83 billion in the prior quarter, while inventory rose slightly to $71.2 million [11] Shareholder Returns - The company repurchased 165,778 shares for a total cost of $74.7 million and declared a cash dividend of $1.74 per share, payable on December 26, 2025 [12]